Fisher & Paykel Healthcare Corp Ltd
FPH: XASX (AUS)
| Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
|---|---|---|---|
| LOCK|.? | LOCK|D<>! | LOCK|msY%^W? |
Fisher & Paykel Healthcare: Fiscal 2026 Guidance Reaffirmed on Minimal Expected Tariff Impact
Fisher & Paykel Healthcare reiterated fiscal 2026 revenue guidance of NZD 2.15 billion-NZD 2.25 billion and NPAT guidance of NZD 390 million-NZD 440 million. The first half is tracking well, with Fisher expecting NZD 1.08 billion in revenue and NPAT of NZD 200 million, implying 13% and 31% growth.
